Structure Therapeutics Inc. (GPCR) stock
GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$18.17−0.40 (-2.15%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Structure Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Structure Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$220.29M. For fiscal 2025 it was -$222.20M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$222.20M | – |
| FY2024 | Dec 31, 2024 | -$116.64M | – |
| FY2023 | Dec 31, 2023 | -$79.49M | – |
| FY2022 | Dec 31, 2022 | -$46.12M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$120.12M | – |
| Q1 FY2026 | Mar 31, 2026 | $15.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$64.42M | – |
| Q3 FY2025 | Sep 30, 2025 | -$51.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$54.56M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.31M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.03M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.10M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.52M | – |
See a number that looks wrong?